U.S. Banks Stock News

NYSE:AWR
NYSE:AWRWater Utilities

The Bull Case For American States Water (AWR) Could Change Following Rising Government Deals And SG Americas’ Stake Shift

In February 2026, American States Water’s board met to review the company’s 2026 operating budget, while CEO Robert J. Sprowls’ estimated 2025 compensation reached US$5,028,665, up modestly from 2024. At the same time, the company secured more than US$74.00 million in government contracts and saw major institutional investors, including SG Americas Securities LLC, significantly increase their holdings, underscoring growing institutional interest and reliance on public-sector revenues. Now...
NYSE:OXY
NYSE:OXYOil and Gas

Is Occidental Petroleum (OXY) Pricing In Too Much Optimism After Its Strong 1 Year Rally?

If you are wondering whether Occidental Petroleum at around US$62.96 offers value or is primarily driven by sentiment, this article walks through the numbers so you can assess the price tag with more confidence. The stock recently saw a 5.0% decline over the last 7 days, alongside a 16.2% gain over 30 days and returns of 48.6% year to date and 66.0% over 1 year. Recent attention on Occidental Petroleum has focused on its role in the US energy sector and how investors interpret its exposure...
NasdaqCM:ASTH
NasdaqCM:ASTHHealthcare

Is Astrana Health (ASTH) Offering Value After Recent Share Price Rebound?

If you are wondering whether Astrana Health at around US$26 is offering good value or fresh risk, it helps to compare the share price with what the underlying business might be worth. The stock has recently moved, with returns of 6.8% over the last 7 days and 4.4% over the past month, while the 1 year return sits at an 11.2% decline and the 3 year return at a 33.2% decline. This can change how the market views both its potential and its risks. These moves come as investors continue to assess...
NYSE:RDN
NYSE:RDNDiversified Financial

Radian Group Inigo Deal Shifts Earnings Mix Beyond US Housing Cycle

Radian Group (NYSE:RDN) has agreed to acquire specialty insurer and reinsurer Inigo, expanding beyond its core mortgage insurance business. The deal adds specialty P&C and reinsurance exposure to Radian's portfolio, reshaping the company's overall business mix. This transaction marks a meaningful shift in Radian's long term risk profile and revenue sources away from exclusive reliance on the US housing market. For investors watching Radian Group at a share price of $33.97, this move arrives...
NasdaqGS:VISN
NasdaqGS:VISNCommunications

A Look At Vistance Networks (VISN) Valuation After Its Recent Rebrand And Share Price Momentum

Event context and recent price performance Vistance Networks (VISN) has drawn fresh attention after its recent rebranding from CommScope Holding Company, with shares last closing at $18.75 and showing positive moves over the past week and month. See our latest analysis for Vistance Networks. The recent rebrand comes alongside strong momentum, with an 8.95% 1 month share price return and a very large 1 year total shareholder return of 415.11%, which contrasts with more modest gains over...
NYSE:PKG
NYSE:PKGPackaging

A Look At Packaging Corp Of America (PKG) Valuation As Shares Show Mixed Recent Returns

Event context and recent performance snapshot Packaging Corporation of America (PKG) is drawing investor attention after recent share price moves, with the stock up about 0.5% over the past day but showing declines over the week, month, and past 3 months. See our latest analysis for Packaging Corporation of America. That 0.5% 1 day share price return sits against a weaker recent pattern, with the 30 day share price return of 7.7% and year to date share price return of 2.7% both in decline. At...
NasdaqCM:SLNO
NasdaqCM:SLNOBiotechs

A Look At Soleno Therapeutics (SLNO) Valuation After Its Recent Share Price Surge

Soleno Therapeutics stock overview Soleno Therapeutics (SLNO) has drawn fresh attention after a sharp 32.3% one day move, capping a month gain of 31.7%. That kind of short term swing naturally raises valuation and risk questions for investors. See our latest analysis for Soleno Therapeutics. The sharp 32.3% one day share price return and 71.7% 7 day share price return come after a 10.8% year to date share price gain, set against a 1 year total shareholder return of about 25% decline and a...
NasdaqGS:IBOC
NasdaqGS:IBOCBanks

International Bancshares (IBOC) Valuation Check After Dividend Hike And Full Year 2025 Results

Dividend hike and full year results put International Bancshares in focus International Bancshares (IBOC) is back on investor radars after the board approved a $0.73 per share cash dividend, a 4.3% increase, alongside the release of full year 2025 financial results. See our latest analysis for International Bancshares. At a share price of $68.26, International Bancshares has seen a 1-day share price return of 0.72% and a 1-month share price return of 2.60%, while the 1-year total shareholder...
NYSE:LBRT
NYSE:LBRTEnergy Services

Has Liberty Energy (LBRT) Run Too Far After A 170% One Year Share Price Surge

This article explores whether Liberty Energy's share price still reflects good value, or if the easier gains may already have occurred, by considering what the current price might be implying about the company. Liberty Energy closed at US$27.67, with a 4.1% decline over the last 7 days, a 3.2% gain over 30 days, a 46.6% return year to date, and a 169.7% return over the past year. Recent coverage has focused on Liberty Energy as part of broader discussions around US energy services companies...
NYSE:VGNT
NYSE:VGNTAuto Components

Versigent Spin Off From Aptiv Resets Board Priorities And Investor Focus

Versigent PLC (NYSE:VGNT) has completed its spin-off from Aptiv’s Electrical Distribution Systems business, forming an independent publicly listed company. The separation was accompanied by a broad refresh of the board and executive team, including new CEO and CFO appointments and restructured board committees. Versigent converted from a limited company to a public limited company, adopted a new name and bylaws, and was added to several major equity benchmarks. Versigent now trades as...
NasdaqCM:MLTX
NasdaqCM:MLTXBiotechs

How MoonLake’s Phase 3 Sonelokimab HiSCR75 Data in HS Could Shape MoonLake Immunotherapeutics (MLTX) Investors

MoonLake Immunotherapeutics recently reported long-term Week 40 Phase 3 VELA-1 and VELA-2 data for sonelokimab in moderate-to-severe hidradenitis suppurativa, showing strong efficacy on HiSCR75 and quality-of-life endpoints with a stable safety profile. An interesting feature of these results is the use of a higher HiSCR75 threshold as the primary endpoint, positioning sonelokimab against existing IL-17A and IL-17A/F therapies on a more stringent efficacy measure. We’ll now examine how...
NYSE:WS
NYSE:WSMetals and Mining

Assessing Worthington Steel (WS) Valuation After Q3 Earnings Update And Dividend Reaffirmation

Worthington Steel (WS) is back in focus after reporting third quarter results that showed higher sales but lower quarterly net income compared with a year earlier, along with higher nine-month earnings and a reaffirmed quarterly dividend. See our latest analysis for Worthington Steel. The latest results and dividend decision come after a mixed price pattern, with a 5.05% 7 day share price return, a 19.61% 30 day share price decline, and a 31.76% 1 year total shareholder return, suggesting...
NasdaqGS:GILT
NasdaqGS:GILTCommunications

Does Gilat Satellite Networks' (GILT) New U.S. Army Orders Reframe Its Defense-Led Connectivity Strategy?

In March 2026, Gilat Satellite Networks’ Gilat DataPath unit reported receiving about US$6,000,000 in new orders over six months to continue providing field and technical services that support U.S. Army global communications operations under the GTACS II contract vehicle. This extension deepens Gilat’s multi-year role in mission-critical U.S. defense communications, underscoring the company’s position as a trusted supplier of resilient connectivity for military operations. We’ll now examine...
NasdaqGS:PDFS
NasdaqGS:PDFSSemiconductor

Is PDF Solutions (PDFS) Quietly Becoming a Core Data Layer for Complex Chip Manufacturing?

Recent commentary highlights how PDF Solutions has been benefiting from AI-led digital transformation, as customers increasingly adopt its cloud-enabled software, unified data platforms, and real-time analytics to manage more complex semiconductor manufacturing. An important insight is that rising investments in 3D manufacturing, AI-driven collaboration, and geographic diversification are amplifying demand for PDF Solutions’ consulting, research, cybersecurity, and compliance-focused...
NasdaqGS:SOLS
NasdaqGS:SOLSChemicals

Why Solstice Advanced Materials (SOLS) Is Up 7.8% After Hudson Licensing Deal For HFO Refrigerants

In late March 2026, Hudson Technologies announced a licensing agreement with Solstice Advanced Materials to reclaim and resell Solstice’s patented lower-GWP HFO refrigerant blends R-448A and R-449A across the United States and Canada under AIM Act-compliant applications in the supermarket segment. This agreement gives Solstice broader access to the refrigeration retrofit market while aligning its technology with tightening environmental regulations on higher-GWP refrigerants. Next, we’ll...
NasdaqGM:PAYO
NasdaqGM:PAYODiversified Financial

Assessing Payoneer Global (PAYO) Valuation After BofA’s New Positive Coverage And Growth Outlook

Why BofA’s New Coverage Matters For Payoneer Global (PAYO) BofA’s decision to initiate coverage of Payoneer Global (PAYO) with a favorable view puts fresh attention on the stock and highlights its role in cross border payments for small and medium sized businesses. See our latest analysis for Payoneer Global. Despite BofA’s positive coverage, momentum has been mixed. There has been a 7 day share price return of 3.14% and a 30 day share price return of 4.68%, set against a 1 year total...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

How Prospective US Tariffs on Branded Drug Imports Will Impact Collegium Pharmaceutical (COLL) Investors

In early April 2026, reports that the US government may impose tariffs of up to 100% on imports of branded and patented drugs, focusing on companies that have not agreed to lower prices, triggered a broad reassessment of regulatory and cost risks across the pharmaceutical industry. This policy debate matters for Collegium Pharmaceutical because it highlights how fast-changing US drug-pricing and trade actions can influence sentiment toward specialty pain and CNS drug makers, even when their...
NYSE:CYD
NYSE:CYDMachinery

China Yuchai International (CYD) Is Up 8.1% After 40% EPS Upgrade Has The Bull Case Changed?

Recently, analysts raised their full-year earnings projections for China Yuchai International by 40.5%, while the company’s year-to-date return has outpaced both the broader Auto-Tires-Trucks sector and its Automotive - Original Equipment peers. This combination of sharply upgraded earnings expectations and clear relative performance strength suggests analysts and investors are reassessing the company’s profit and competitive outlook. We’ll now explore how this upgrade in earnings...
NYSE:EW
NYSE:EWMedical Equipment

Edwards Lifesciences (EW) Valuation Check After EVOQUE TRISCEND II Results And Growing Regulatory Momentum

Edwards Lifesciences (EW) put fresh clinical data for its EVOQUE tricuspid valve system in the spotlight at the ACC.26 conference, highlighting sustained patient benefits and lower mortality in the TRISCEND II trial. See our latest analysis for Edwards Lifesciences. At a share price of $81.19, Edwards Lifesciences has seen a 17.67% 1 year total shareholder return. The 90 day share price return of a 5.43% decline suggests recent momentum has cooled despite supportive EVOQUE trial headlines. If...
NasdaqGS:SRRK
NasdaqGS:SRRKBiotechs

A Look At Scholar Rock (SRRK) Valuation After Apitegromab BLA Resubmission And Reduced Regulatory Risk

Scholar Rock Holding (SRRK) has resubmitted its Biologics License Application for apitegromab to the FDA, following alignment with regulators on facility remediation and the addition of a second US based fill finish site. See our latest analysis for Scholar Rock Holding. The BLA resubmission appears to have kept attention on Scholar Rock, with a 7 day share price return of 13.3% and an 18.16% 90 day share price return. The 1 year total shareholder return of 87.44% points to strong momentum...
NYSE:ORA
NYSE:ORARenewable Energy

Should Ormat’s 149 MW Geothermal and Storage Expansion Plans Require Action From Ormat Technologies (ORA) Investors?

In recent months, Ormat Technologies has outlined plans to add 149 MW of new capacity by the end of 2027, including 101 MW from geothermal projects, while committing US$180 million to build additional energy storage assets in the United States through 2028. This combination of geothermal expansion and sizable storage investment highlights Ormat’s effort to deepen its role in supplying grid-stable renewable power as adoption of clean energy accelerates. Next, we’ll explore how Ormat’s planned...
NYSE:CNA
NYSE:CNAInsurance

Assessing CNA Financial (CNA) Valuation After Earnings Miss And Higher Dividend

Why CNA Financial (CNA) Is Back in Focus After Its Latest Quarter CNA Financial (CNA) has drawn fresh attention after quarterly results came in below market expectations, with weaker core earnings per share and profitability despite growth in premiums and investment income. At the same time, management raised the regular dividend by 4% and announced a special dividend. This move highlights confidence in ongoing cash generation, even as underwriting performance and higher expenses remain key...
NasdaqGS:MEDP
NasdaqGS:MEDPLife Sciences

Medpace Holdings (MEDP) Is Up 7.8% After GLP-1 Trials Drive 32% Revenue Jump – What’s Changed

In the fourth quarter of 2025, Medpace Holdings reported a 32% year-over-year revenue increase, while Mairs & Power Small Cap Fund cited the company as a key contributor in its investor letter due to stronger clinical trial trends linked to GLP-1 programs. This combination of healthier trial cancellation patterns and momentum in GLP-1 research highlights how Medpace is benefiting from current demand in metabolic-related clinical development. We’ll now explore how this improved GLP-1-driven...
NYSE:ARDT
NYSE:ARDTHealthcare

Does Ardent Health (ARDT) Leadership Turnover Foreshadow Deeper Questions About Its Hospital Operations Strategy?

On March 24, 2026, Ardent Health, Inc. announced that Ethan Chernin departed the company and would no longer serve as President, Hospital Services, with his separation treated as a “Qualifying Termination” under the firm’s Executive Severance Plan. This leadership change in a core operating role raises important questions about continuity in hospital operations and the company’s broader execution plans. We’ll now examine how the sudden exit of Ardent’s President of Hospital Services may...